Velocity Day Highlights

Here's what you can look forward to on Velocity Day. Join us and be part of an unstoppable movement that provides hope and support to cancer patients and their families across the world.

 

Velocity Activities

DONATE TODAY

Rider Details

Your Way Details

Official Velocity Playlist

Join our Strava Club

 

Your Impact

100% of funds raised by the Velocity community support expert patient care and life-changing research at Columbia’s Herbert Irving Comprehensive Cancer Center. Click here to learn more.

 


2021 Velocity Fellows

 
Thanks to the funds you raised from last year’s Velocity, these four researchers will receive seed funding for innovative pilot projects aimed at improving detection and treatment of breast, brain, and gastrointestinal cancers. This is just one way the Velocity community fuels groundbreaking research that saves lives. To learn more about the Velocity Fellows and their projects, hover over their photos below.

Neil Vasan, MD, PhD

Assistant Professor of Medicine at VP&S

“Large scale functional examination of PIK3CA variants and PI3K inhibitor sensitivity in breast cancer”
Dr. Vasan plans to develop a mutational scanning platform to measure the functional and therapeutic impact of all single amino acid PIK3CA variants. Such a compendium would provide a roadmap to guide current and future treatment strategies for patients with breast cancer and other tumor types. 

“Large scale functional examination of PIK3CA variants and PI3K inhibitor sensitivity in breast cancer”
Dr. Vasan plans to develop a mutational scanning platform to measure the functional and therapeutic impact of all single amino acid PIK3CA variants. Such a compendium would provide a roadmap to guide current and future treatment strategies for patients with breast cancer and other tumor types. 

Lauren Houghton, PhD

Assistant Professor of Epidemiology, MPH

“NEW PARADIGM Breast Cancer in Black Women”
Dr. Houghton’s mixed-method project will explore the potential of the full steroid metabolome, which includes metabolic components typically thought of as “stress” and “male” hormones, to independently predict early-onset breast cancer in Black and white women. She will also interview Black women to understand their perspective of using biomarkers in cancer screening. 

“NEW PARADIGM Breast Cancer in Black Women”
Dr. Houghton’s mixed-method project will explore the potential of the full steroid metabolome, which includes metabolic components typically thought of as “stress” and “male” hormones, to independently predict early-onset breast cancer in Black and white women. She will also interview Black women to understand their perspective of using biomarkers in cancer screening. 

Chin Hur, MD

Professor of Medicine, VP&S

“Real World Integration of Liquid Biopsy Cancer Tests into Gastrointestinal Cancer Early Detection”
Dr. Hur and collaborators aim to use innovative deployment of simulation modeling and data-driven investigation to inform the utilization of liquid biopsy tests for cancer early detection and control. In particular, the study will analyze the potential integration of liquid biopsy testing for colorectal cancer, gastric cancer, and esophageal cancer screening in the context of endoscopic screening and surveillance.

“Real World Integration of Liquid Biopsy Cancer Tests into Gastrointestinal Cancer Early Detection”
Dr. Hur and collaborators aim to use innovative deployment of simulation modeling and data-driven investigation to inform the utilization of liquid biopsy tests for cancer early detection and control. In particular, the study will analyze the potential integration of liquid biopsy testing for colorectal cancer, gastric cancer, and esophageal cancer screening in the context of endoscopic screening and surveillance.

Markus D. Siegelin, MD

Associate Professor of Pathology and Cell Biology at VP&S

“Targeting Metabolic Liabilities Induced by AURKA Inhibition in Glioblastoma”
Dr. Siegelin aims to investigate whether the anabolic tumor cell metabolism of glioblastomas is regulated through Aurora kinase A (AURKA), an enzyme that shows significantly higher expression in cancer tissues than in normal control tissues for multiple tumor types. The results will provide further biological insight of the underlying molecular pathways involved in glioblastoma, which may facilitate combination treatment strategies involving AURKA inhibition. 

“Targeting Metabolic Liabilities Induced by AURKA Inhibition in Glioblastoma”
Dr. Siegelin aims to investigate whether the anabolic tumor cell metabolism of glioblastomas is regulated through Aurora kinase A (AURKA), an enzyme that shows significantly higher expression in cancer tissues than in normal control tissues for multiple tumor types. The results will provide further biological insight of the underlying molecular pathways involved in glioblastoma, which may facilitate combination treatment strategies involving AURKA inhibition. 

Sponsor Row

Thank you to our sponsors!

Be Social

Use #VelocityRide and #YourVelocity all week to have your posts and photos automatically added below!*

*Profile must be set to public.